# A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

> **NCT06542250** · PHASE1,PHASE2 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 174 (estimated)

## Conditions studied

- B-cell Malignancies

## Interventions

- **DRUG:** AZD5492

## Key facts

- **NCT ID:** NCT06542250
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-18
- **Primary completion:** 2028-02-14
- **Final completion:** 2028-02-14
- **Target enrollment:** 174 (ESTIMATED)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06542250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06542250, "A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT06542250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*